17 December 2018
("ImmuPharma" or the "Company")
APPOINTMENT OF NOMINATED ADVISOR
ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company is pleased to announce the appointment of SPARK Advisory Partners Limited ("SPARK") as the Company's Nominated Advisor ("NOMAD"), with immediate effect.
Commenting on the appointment, ImmuPharma's Chairman, Tim McCarthy, said:
"I am delighted to announce the appointment of SPARK as the Company's NOMAD. We look forward to working with the team going forward, alongside our joint brokers, Stanford Capital Partners and SI Capital."
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. ("MAR")
For further information please contact:
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.